Cargando…

Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery

Pulmonary hypertension (PH) is a progressive disease that eventually leads to heart failure and potentially death for some patients. There are many unique advantages to treating pulmonary diseases directly and non-invasively by inhalation aerosols and dry powder inhalers (DPIs) possess additional un...

Descripción completa

Detalles Bibliográficos
Autores principales: Muralidharan, Priya, Hayes, Don, Fineman, Jeffrey R., Black, Stephen M., Mansour, Heidi M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707591/
https://www.ncbi.nlm.nih.gov/pubmed/34959469
http://dx.doi.org/10.3390/pharmaceutics13122188
_version_ 1784622473757589504
author Muralidharan, Priya
Hayes, Don
Fineman, Jeffrey R.
Black, Stephen M.
Mansour, Heidi M.
author_facet Muralidharan, Priya
Hayes, Don
Fineman, Jeffrey R.
Black, Stephen M.
Mansour, Heidi M.
author_sort Muralidharan, Priya
collection PubMed
description Pulmonary hypertension (PH) is a progressive disease that eventually leads to heart failure and potentially death for some patients. There are many unique advantages to treating pulmonary diseases directly and non-invasively by inhalation aerosols and dry powder inhalers (DPIs) possess additional unique advantages. There continues to be significant unmet medical needs in the effective treatment of PH that target the underlying mechanisms. To date, there is no FDA-approved DPI indicated for the treatment of PH. Fasudil is a novel RhoA/Rho kinase (ROCK) inhibitor that has shown great potential in effectively treating pulmonary hypertension. This systematic study is the first to report on the design and development of DPI formulations comprised of respirable nanoparticles/microparticles using particle engineering design by advanced spray drying. In addition, comprehensive physicochemical characterization, in vitro aerosol aerosol dispersion performance with different types of human DPI devices, in vitro cell-drug dose response cell viability of different human respiratory cells from distinct lung regions, and in vitro transepithelial electrical resistance (TEER) as air-interface culture (AIC) demonstrated that these innovative DPI fasudil formulations are safe on human lung cells and have high aerosol dispersion performance properties.
format Online
Article
Text
id pubmed-8707591
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87075912021-12-25 Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery Muralidharan, Priya Hayes, Don Fineman, Jeffrey R. Black, Stephen M. Mansour, Heidi M. Pharmaceutics Article Pulmonary hypertension (PH) is a progressive disease that eventually leads to heart failure and potentially death for some patients. There are many unique advantages to treating pulmonary diseases directly and non-invasively by inhalation aerosols and dry powder inhalers (DPIs) possess additional unique advantages. There continues to be significant unmet medical needs in the effective treatment of PH that target the underlying mechanisms. To date, there is no FDA-approved DPI indicated for the treatment of PH. Fasudil is a novel RhoA/Rho kinase (ROCK) inhibitor that has shown great potential in effectively treating pulmonary hypertension. This systematic study is the first to report on the design and development of DPI formulations comprised of respirable nanoparticles/microparticles using particle engineering design by advanced spray drying. In addition, comprehensive physicochemical characterization, in vitro aerosol aerosol dispersion performance with different types of human DPI devices, in vitro cell-drug dose response cell viability of different human respiratory cells from distinct lung regions, and in vitro transepithelial electrical resistance (TEER) as air-interface culture (AIC) demonstrated that these innovative DPI fasudil formulations are safe on human lung cells and have high aerosol dispersion performance properties. MDPI 2021-12-17 /pmc/articles/PMC8707591/ /pubmed/34959469 http://dx.doi.org/10.3390/pharmaceutics13122188 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Muralidharan, Priya
Hayes, Don
Fineman, Jeffrey R.
Black, Stephen M.
Mansour, Heidi M.
Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery
title Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery
title_full Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery
title_fullStr Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery
title_full_unstemmed Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery
title_short Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery
title_sort advanced microparticulate/nanoparticulate respirable dry powders of a selective rhoa/rho kinase (rock) inhibitor for targeted pulmonary inhalation aerosol delivery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707591/
https://www.ncbi.nlm.nih.gov/pubmed/34959469
http://dx.doi.org/10.3390/pharmaceutics13122188
work_keys_str_mv AT muralidharanpriya advancedmicroparticulatenanoparticulaterespirabledrypowdersofaselectiverhoarhokinaserockinhibitorfortargetedpulmonaryinhalationaerosoldelivery
AT hayesdon advancedmicroparticulatenanoparticulaterespirabledrypowdersofaselectiverhoarhokinaserockinhibitorfortargetedpulmonaryinhalationaerosoldelivery
AT finemanjeffreyr advancedmicroparticulatenanoparticulaterespirabledrypowdersofaselectiverhoarhokinaserockinhibitorfortargetedpulmonaryinhalationaerosoldelivery
AT blackstephenm advancedmicroparticulatenanoparticulaterespirabledrypowdersofaselectiverhoarhokinaserockinhibitorfortargetedpulmonaryinhalationaerosoldelivery
AT mansourheidim advancedmicroparticulatenanoparticulaterespirabledrypowdersofaselectiverhoarhokinaserockinhibitorfortargetedpulmonaryinhalationaerosoldelivery